CN103228291A - 用于b细胞淋巴瘤的联合疗法 - Google Patents

用于b细胞淋巴瘤的联合疗法 Download PDF

Info

Publication number
CN103228291A
CN103228291A CN2011800548133A CN201180054813A CN103228291A CN 103228291 A CN103228291 A CN 103228291A CN 2011800548133 A CN2011800548133 A CN 2011800548133A CN 201180054813 A CN201180054813 A CN 201180054813A CN 103228291 A CN103228291 A CN 103228291A
Authority
CN
China
Prior art keywords
antibodies
cell
seq
aminoacid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800548133A
Other languages
English (en)
Chinese (zh)
Inventor
R·赫伯斯特
E·K·沃德
K·P·麦基弗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
MedImmune Vaccines Inc
Original Assignee
MedImmune Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Vaccines Inc filed Critical MedImmune Vaccines Inc
Publication of CN103228291A publication Critical patent/CN103228291A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2011800548133A 2010-11-15 2011-11-14 用于b细胞淋巴瘤的联合疗法 Pending CN103228291A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41377110P 2010-11-15 2010-11-15
US61/413,771 2010-11-15
PCT/US2011/060520 WO2012067981A1 (en) 2010-11-15 2011-11-14 Combination therapy for b cell lymphomas

Publications (1)

Publication Number Publication Date
CN103228291A true CN103228291A (zh) 2013-07-31

Family

ID=46084355

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800548133A Pending CN103228291A (zh) 2010-11-15 2011-11-14 用于b细胞淋巴瘤的联合疗法

Country Status (11)

Country Link
US (1) US20130330328A1 (enExample)
EP (1) EP2640416A4 (enExample)
JP (1) JP2013543869A (enExample)
KR (1) KR20130130726A (enExample)
CN (1) CN103228291A (enExample)
AU (1) AU2011329161A1 (enExample)
CA (1) CA2817842A1 (enExample)
MX (1) MX2013005270A (enExample)
RU (1) RU2013127115A (enExample)
SG (1) SG190254A1 (enExample)
WO (1) WO2012067981A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110945028A (zh) * 2017-07-10 2020-03-31 国际药物发展生物技术公司 用非岩藻糖基化促凋亡抗cd19抗体与抗cd20抗体或化疗剂联合治疗b细胞恶性肿瘤
CN114364698A (zh) * 2019-08-21 2022-04-15 吉尼瑞姆股份公司 结合cd3的互补决定区和含所述cdr的双特异性抗原结合分子
CN116390933A (zh) * 2020-11-06 2023-07-04 诺华股份有限公司 治疗b细胞恶性肿瘤的抗cd19剂和b细胞靶向剂组合疗法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2981046T3 (es) * 2016-05-30 2024-10-07 Incyte Corp Métodos para predecir el beneficio terapéutico de una terapia anti-CD19 en pacientes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080138336A1 (en) * 2006-09-08 2008-06-12 Medlmmune, Inc. Humanized Anti-CD19 Antibodies And Their Use In Treatment Of Oncology, Transplantation And Autoimmune Disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1853718E (pt) * 2005-02-15 2015-11-12 Univ Duke Anticorpos anti-cd19 e usos em oncologia
CN105837690A (zh) * 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080138336A1 (en) * 2006-09-08 2008-06-12 Medlmmune, Inc. Humanized Anti-CD19 Antibodies And Their Use In Treatment Of Oncology, Transplantation And Autoimmune Disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KEICHIRO MIHARA ET AL: "Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma", 《BRITISH JOURNAL OF HAEMATOLOGY》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110945028A (zh) * 2017-07-10 2020-03-31 国际药物发展生物技术公司 用非岩藻糖基化促凋亡抗cd19抗体与抗cd20抗体或化疗剂联合治疗b细胞恶性肿瘤
CN110945028B (zh) * 2017-07-10 2023-09-08 国际药物发展生物技术公司 用非岩藻糖基化促凋亡抗cd19抗体与抗cd20抗体或化疗剂联合治疗b细胞恶性肿瘤
CN114364698A (zh) * 2019-08-21 2022-04-15 吉尼瑞姆股份公司 结合cd3的互补决定区和含所述cdr的双特异性抗原结合分子
CN114364698B (zh) * 2019-08-21 2024-05-28 吉尼瑞姆股份公司 结合cd3的互补决定区和含所述cdr的双特异性抗原结合分子
CN116390933A (zh) * 2020-11-06 2023-07-04 诺华股份有限公司 治疗b细胞恶性肿瘤的抗cd19剂和b细胞靶向剂组合疗法

Also Published As

Publication number Publication date
JP2013543869A (ja) 2013-12-09
SG190254A1 (en) 2013-06-28
CA2817842A1 (en) 2012-05-24
EP2640416A4 (en) 2014-04-23
US20130330328A1 (en) 2013-12-12
EP2640416A1 (en) 2013-09-25
WO2012067981A1 (en) 2012-05-24
RU2013127115A (ru) 2014-12-27
KR20130130726A (ko) 2013-12-02
MX2013005270A (es) 2013-10-25
AU2011329161A1 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
CN105012953B (zh) 用cd37-特异性和cd20-特异性结合分子减少b-细胞
CN105198997B (zh) Cd37免疫治疗剂及其与双功能化学治疗剂的联合
RU2756010C2 (ru) Комбинация антитела к CD19 и ингибитора тирозинкиназы брутона и их применение
CN109476739A (zh) 用于肿瘤特异性细胞消减的抗CD25 FCγ受体双特异性抗体
Parihar et al. IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells
CN103827143A (zh) 抗cd20抗体和抗gm-csf抗体的治疗性组合产品及其用途
CN109476752A (zh) 抗-pd-1抗体与抗-cd30抗体的组合在淋巴瘤治疗中的用途
KR20140084244A (ko) 항-cd20 항체와 인간 il-15를 사용한 병용치료
KR20180042335A (ko) 조합 및 이의 용도
CN109475633A (zh) 在难治性霍奇金淋巴瘤中用纳武单抗阻断pd-1
CN101678101B (zh) 可用于诊断和治疗b细胞慢性淋巴细胞白血病的能够在肿瘤细胞中诱导凋亡的药物组合物
TW202216193A (zh) 包含抗CD19抗體及阻斷SIRPα-CD47先天免疫檢查點之多肽之抗腫瘤組合療法
CN1494433A (zh) Cd23拮抗剂用于治疗肿瘤性疾病的用途
US20250074981A1 (en) Combination therapy with dexamethasone and tumor-specific t cell engaging multi-specific antibodies for treating cancer
PT1758610E (pt) Métodos para o tratamento de cancro utilizando terapia com il-21 e anticorpos monoclonais
CN101218351A (zh) 抗cd19抗体及其在肿瘤学中的应用
US20130330328A1 (en) Combination Therapy For B Cell Lymphomas
US11634488B2 (en) Treatment of B cell malignancies using afucosylated pro-apoptotic anti-CD19 antibodies in combination with anti CD20 antibodies or chemotherapeutics
Yang et al. Fc-enhanced anti-TIGIT antibody 30,278-IgG1 RMD amplifies antitumor immunity through effector cell activation and synergizes with PD-1 blockade
CN110526972A (zh) 一种抗cd47抗体在制备治疗淋巴瘤的药物中的用途
US20250171533A1 (en) Kir3dl3 inhibitors and immune cell activating agents
CN121335924A (zh) Cd74 car-t疗法及其使用方法
Peri Next generation anti-CD20 monoclonal antibodies and their mechanisms of action against B-cell lymphomas
Haddley Otlertuzumab
Peri Next generation monoclonal antibodies and their mechanisms of action against B-cell lymphomas

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20130731